Meet us at ACS FALL 18 - 20 August
ODISEI Organoid-based Discovery Platform Introduction
Home » Latest Research Trends » Patient Derived Tumoroids of High Grade Neuroendocrine Neoplasms for More Personalized Therapies

Patient Derived Tumoroids of High Grade Neuroendocrine Neoplasms for More Personalized Therapies

In the absence of predictive biomarkers and representative preclinical models for high-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), a fatal and heterogeneous malignancy, researchers established patient-derived (PD) tumoroids from biobanked tissue samples. This model facilitated rapid ex vivo pharmacotyping, next-generation sequencing, and perturbational profiling. PD tumoroids accurately mirrored biological features of high-grade GEP-NEN and replicated clinical responses to cisplatin and temozolomide. Investigation of treatment-induced adaptive stress responses identified synergistic effects of Lysine demethylase 5 A and interferon-beta with cisplatin. Notably, ex vivo drug response correlated with patients’ clinical responses, suggesting potential for personalized therapeutic options for advanced high-grade GEP-NEN.

Keywords: Organoids, tumoroids, neuroendocrine, personalized therapy, neoplasms

Subscribe
to the latest updates in the newsletter

Related Solutions

  • Disease Modeling
  • Oncology
  • Organoid
  • Cosmetics
  • OECD TG
  • Zebrafish
  • Bioinfomatics
  • Live&3D Imaging
  • Molecular biology
  • Spatial Biology

Next Articles

Connect with Us